MarketCapExport financials
AxoGen (AXGN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AxoGen Balance Sheet 2025-2009 | AXGN
Brief overview of AxoGen's assets and capital
The comparison uses five available annual reports from the 2021–2025 interval.
Across five periods, assets reached $221.7 million versus $208 million initially. Growth of +6.6% reflects gradual development.
Assets outpaced liabilities, +6.6% versus -2.8%. Dependence on external funding declined.
Internal capital represents 58.1% of the balance sheet, previously 54.1%. This is a strong capital position.
Net debt is $15.2 million, or 0.12x of equity. This is a conservative debt position.
The cash share moved from 18.8% to 16%. A higher figure generally provides more room in an adverse scenario.
The balance sheet includes a negative accumulated result of -$307 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
AxoGen's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet AxoGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
15.2 M | 21.9 M | 17.1 M | 31.7 M | 13.9 M | -15.9 M | -32.4 M | -24.2 M | -11.9 M | -5.7 M | -362 K | 16.9 M | 5.29 M | 7.67 M | -3.35 M | - | - |
Long Term Debt |
48.4 M | 47.5 M | 46.6 M | 45.7 M | 44.8 M | 32 M | 1.6 M | 35 K | 19.9 M | 20.3 M | 25.5 M | 25.1 M | 25.4 M | 21.6 M | 4.4 M | - | - |
Long Term Debt Current |
2.35 M | 1.96 M | 1.54 M | 1.3 M | 1.82 M | 846 K | 1.72 M | 28 K | 735 K | 20.9 K | - | - | - | - | 435 K | 7.08 M | - |
Total Non Current Liabilities |
69.3 M | 69.2 M | 70.7 M | 70.6 M | 71.2 M | 55.4 M | 1.61 M | 147 K | 20 M | 20.4 M | 25.6 M | 25.2 M | 25.4 M | 21.6 M | 4.4 M | 8.72 M | - |
Total Current Liabilities |
23.6 M | 30.6 M | 30.4 M | 23.8 M | 24.3 M | 22.8 M | 20.9 M | 13 M | 13.7 M | 11.1 M | 3.71 M | 2.45 M | 2.1 M | 1.48 M | 2.02 M | 9.39 M | - |
Total Liabilities |
92.8 M | 99.8 M | 101 M | 94.4 M | 95.5 M | 78.2 M | 22.5 M | 13.2 M | 33.7 M | 31.4 M | 29.4 M | 27.6 M | 27.5 M | 23.1 M | 6.42 M | 18.1 M | - |
Deferred Revenue |
- | - | - | - | 14 K | 14 K | 14 K | 18 K | 31.7 K | 33.3 K | 14.1 K | 14.1 K | 14.1 K | - | - | - | - |
Retained Earnings |
-307 M | -291 M | -281 M | -260 M | -231 M | -204 M | -180 M | -151 M | -128 M | -118 M | -103 M | -90.1 M | -72.4 M | -57.8 M | -48.4 M | -38.2 M | - |
Total Assets |
222 M | 204 M | 197 M | 195 M | 208 M | 201 M | 155 M | 160 M | 58.9 M | 46.4 M | 37.5 M | 16.4 M | 27.7 M | 20.2 M | 12.5 M | 6.41 M | - |
Cash and Cash Equivalents |
35.5 M | 27.6 M | 31 M | 15.3 M | 32.8 M | 48.8 M | 35.7 M | 24.3 M | 36.5 M | 30 M | 25.9 M | 8.22 M | 20.1 M | 13.9 M | 8.19 M | 1.8 M | 283 K |
Book Value |
129 M | 104 M | 95.7 M | 101 M | 113 M | 123 M | 132 M | 147 M | 25.2 M | 14.9 M | 8.2 M | -11.2 M | 137 K | -2.83 M | 6.07 M | -11.7 M | - |
Total Shareholders Equity |
129 M | 104 M | 95.7 M | 101 M | 113 M | 123 M | 132 M | 147 M | 25.2 M | 14.9 M | 8.2 M | -11.2 M | 137 K | -2.83 M | 6.07 M | -27.1 M | -28.6 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet AxoGen
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
17.6 M | 18.1 M | 18.5 M | 16.8 M | 17.4 M | 18 M | 18.6 M | 19.2 M | 19.7 M | 20.2 M | 20.7 M | 21.1 M | 19.9 M | 20.1 M | 20.1 M | 20.4 M | 20.6 M | 2 K | 20.9 M | 20.8 M | 21.3 M | 20.3 M | 20.7 M | 20.9 M | 19 M | 1.63 M | 1.16 M | 1.56 M | 1.97 M | 2.34 M | 3.18 M | 35 K | 38.3 K | 45.2 K | 17.8 M | 19.8 M | 20.4 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 24.7 M | - | - | - | 25.1 M | 28.2 M | 27.2 M | 26.3 M | 25.4 M | 24.3 M | 23.4 M | 22.4 M | 21.6 M | 6.75 M | 3.46 M | 3.93 M | 5 M | 4.83 M | 4.4 M | 4.4 M |
Total Non Current Liabilities |
17.8 M | 18.2 M | 18.7 M | 69.3 M | 67.6 M | 68.2 M | 69.1 M | 69.2 M | 69.5 M | 69.8 M | 70.4 M | 70.7 M | 70.2 M | 70.6 M | 70.7 M | 70.6 M | 70.5 M | 70.8 M | 71.2 M | 71.2 M | 71.3 M | 70.2 M | 55.4 M | 55.4 M | 53.4 M | 36.2 M | 1.2 M | 1.61 M | 2.02 M | 2.41 M | 3.26 M | 147 K | 163 K | 183 K | 17.9 M | 20 M | 20.5 M | 20.5 M | 20.5 M | 20.4 M | 25.1 M | 25 M | 24.9 M | 24.8 M | 25.6 M | 25.5 M | 25.4 M | 25.2 M | 28.2 M | 27.3 M | 26.3 M | 25.4 M | 24.3 M | 23.4 M | 22.4 M | 21.6 M | 4.74 M | 3.46 M | 3.93 M | 4.4 M | 4.83 M | 5.81 M | - |
Total Liabilities |
54.2 M | 48.6 M | 44.7 M | 92.8 M | 95.6 M | 93.2 M | 90.8 M | 99.8 M | 92.6 M | 93.2 M | 93.4 M | 101 M | 96.8 M | 94.5 M | 92 M | 94.4 M | 94.1 M | 94.4 M | 94.2 M | 95.5 M | 94.7 M | 91.8 M | 77.7 M | 78.2 M | 72.2 M | 50.2 M | 20.7 M | 22.5 M | 18.8 M | 18.6 M | 19.7 M | 13.2 M | 12.2 M | 10 M | 33.5 M | 33.7 M | 31.7 M | 31.5 M | 31.1 M | 31.4 M | 29.7 M | 29 M | 28.7 M | 28.5 M | 29.7 M | 29 M | 28.8 M | 27.6 M | 30.3 M | 29.6 M | 28.3 M | 27.5 M | 25.6 M | 25 M | 23.9 M | 23.1 M | 8.49 M | 6.57 M | 6.36 M | 6.42 M | 6.48 M | 6.42 M | 6.42 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14 K | 14 K | 14 K | 14 K | 14 K | 14 K | 14 K | 14 K | 14 K | 14 K | 19 K | 24 K | 18 K | 23 K | 27 K | 32.1 K | 32 K | 43.6 K | 39.4 K | 35.2 K | 33.3 K | 36 K | 28.6 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | 14.1 K | - | - | - | - | - | - | - | - |
Retained Earnings |
-326 M | -328 M | -327 M | -307 M | -294 M | -295 M | -295 M | -291 M | -292 M | -290 M | -288 M | -281 M | -277 M | -273 M | -267 M | -260 M | -254 M | -250 M | -242 M | -231 M | -225 M | -218 M | -210 M | -204 M | -198 M | -196 M | -188 M | -180 M | -173 M | -167 M | -160 M | -151 M | -145 M | -141 M | -134 M | -128 M | -126 M | -124 M | -122 M | -118 M | -112 M | -110 M | -107 M | -103 M | -99.9 M | -96.9 M | -93.7 M | -90.1 M | -83.6 M | -80.4 M | -76.6 M | -72.4 M | -68.3 M | -64.7 M | -61.3 M | -57.8 M | -53.8 M | -51.6 M | -50.5 M | -48.4 M | -46.3 M | -1.79 M | -48.4 M |
Total Assets |
550 M | 305 M | 289 M | 222 M | 216 M | 205 M | 196 M | 204 M | 192 M | 189 M | 187 M | 197 M | 195 M | 192 M | 189 M | 195 M | 196 M | 196 M | 198 M | 208 M | 210 M | 211 M | 197 M | 201 M | 194 M | 170 M | 145 M | 155 M | 154 M | 157 M | 160 M | 160 M | 162 M | 161 M | 55.2 M | 58.9 M | 42.2 M | 42.8 M | 43.3 M | 46.4 M | 30.8 M | 31.8 M | 33.5 M | 36.7 M | 40.9 M | 25.4 M | 28.1 M | 16.4 M | 20.1 M | 22.4 M | 24.6 M | 27.7 M | 29.8 M | 15.7 M | 17.9 M | 20.2 M | 9.69 M | 9.84 M | 10.5 M | 12.5 M | 14.4 M | 12.2 M | 12.5 M |
Cash and Cash Equivalents |
331 M | 96.6 M | 84.7 M | 39.5 M | 27.9 M | 26 M | 24.1 M | 33.6 M | 24.7 M | 25.2 M | 21.7 M | 37 M | 37.1 M | 29.5 M | 14 M | 21.5 M | 20.6 M | 18.1 M | 20.8 M | 39 M | 53.1 M | 59.4 M | 46.2 M | 55.6 M | 67.6 M | 85.9 M | 41.9 M | 41.7 M | 30.6 M | 30.9 M | 29.5 M | 30.3 M | 25.6 M | 134 M | 30.6 M | 36.5 M | 22 M | 23.9 M | 25.9 M | 30 M | 16 M | 18.3 M | 20.9 M | 25.9 M | 29.9 M | 15.6 M | 19.3 M | 8.22 M | 11.8 M | 14.2 M | 16.8 M | 20.1 M | 22.6 M | 8.69 M | 11.2 M | 13.9 M | 4.45 M | 4.64 M | 5.64 M | 8.19 M | 10.5 M | 2.23 M | 8.19 M |
Book Value |
496 M | 256 M | 245 M | 129 M | 121 M | 112 M | 105 M | 104 M | 99.4 M | 95.7 M | 93.2 M | 95.7 M | 97.8 M | 97.2 M | 97.5 M | 101 M | 101 M | 102 M | 104 M | 113 M | 115 M | 119 M | 120 M | 123 M | 122 M | 120 M | 124 M | 132 M | 135 M | 138 M | 141 M | 147 M | 149 M | 151 M | 21.7 M | 25.2 M | 10.6 M | 11.3 M | 12.1 M | 14.9 M | 1.1 M | 2.79 M | 4.84 M | 8.2 M | 11.2 M | -3.53 M | -680 K | -11.2 M | -10.2 M | -7.18 M | -3.69 M | 137 K | 4.11 M | -9.3 M | -6.01 M | -2.83 M | 1.2 M | 3.27 M | 4.12 M | 6.07 M | 7.96 M | 5.74 M | 6.07 M |
Total Shareholders Equity |
496 M | 256 M | 245 M | 129 M | 121 M | 112 M | 105 M | 104 M | 99.4 M | 95.7 M | 93.2 M | 95.7 M | 97.8 M | 97.2 M | 97.5 M | 101 M | 101 M | 102 M | 104 M | 113 M | 115 M | 119 M | 120 M | 123 M | 122 M | 120 M | 124 M | 132 M | 135 M | 138 M | 141 M | 147 M | 149 M | 151 M | 21.7 M | 25.2 M | 10.6 M | 11.3 M | 12.1 M | 14.9 M | 1.1 M | 2.79 M | 4.84 M | 8.2 M | 11.2 M | -3.53 M | -680 K | -11.2 M | -10.2 M | -7.18 M | -3.69 M | 137 K | 4.11 M | -9.3 M | -6.01 M | -2.83 M | 1.2 M | 3.27 M | 4.12 M | 6.07 M | 7.96 M | 11.5 M | 6.07 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of AxoGen, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical devices
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Myomo
MYO
|
$ 1.32 | -5.71 % | $ 55.2 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |